本页面由Tiger Trade Technology Pte. Ltd.提供服务

Attovia Therapeutics

14.59
-1.6200-9.99%
盘后:14.590.00000.00%17:26 EDT
成交量:26.23万
成交额:397.47万
市值:6.66亿
市盈率:-9.46
高:16.30
开:16.21
低:14.44
收:16.21
52周最高:28.00
52周最低:14.44
股本:4,565.13万
流通股本:1,700.00万
量比:0.62
换手率:1.54%
股息:- -
股息率:- -
每股收益(TTM):-1.5420
每股收益(LYR):-15.3508
净资产收益率:--
总资产收益率:--
市净率:-4.58
市盈率(LYR):-0.95

数据加载中...

2023/03/13

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2023/03/13

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2023/03/13

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2023/03/03

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/03/02

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/09/08

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/09/08

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/08/18

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/06/06

超过5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2022/05/02

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/23

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2022/02/10

SEC问询函

CORRESP [Cover] - Correspondence
2022/01/24

SEC问询函

CORRESP [Cover] - Correspondence
2021/12/20

SEC问询函

CORRESP [Cover] - Correspondence
2021/12/17

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/22

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/19

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/09

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/07/06

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2020/07/06

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership